Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
- 1 August 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 394 (10199), 672-683
- https://doi.org/10.1016/s0140-6736(19)31791-x
Abstract
No abstract availableFunding Information
- Cancer Research UK (C20/A5860)
- Tehran University of Medical Sciences (81/15)
This publication has 24 references indexed in Scilit:
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseThe New England Journal of Medicine, 2016
- A Polypill Strategy to Improve AdherenceJournal of the American College of Cardiology, 2014
- Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trialEuropean Journal of Preventive Cardiology, 2014
- Polypills for cardiovascular prevention: a step forward?Nature Reviews Cardiology, 2013
- Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVDJAMA, 2013
- Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50 000 adults in IranBMJ, 2012
- Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary careContemporary Clinical Trials, 2011
- A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factorsInternational Journal of Clinical Practice, 2010
- Cohort Profile: The Golestan Cohort Study--a prospective study of oesophageal cancer in northern IranInternational Journal of Epidemiology, 2009
- A strategy to reduce cardiovascular disease by more than 80%BMJ, 2003